Operating Expenses
Acquired IPR&D Expense
Gilead Sciences Acquired IPR&D Expense decreased by 80.1% to $107.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 57.7%, from $253.00M to $107.00M. Over 4 years (FY 2021 to FY 2025), Acquired IPR&D Expense shows relatively stable performance with a 2.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2021
Last reportedQ1 2026May 7, 2026
Metric ID:
abbv_acquired_iprd_expenseHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $234.75M | $234.75M | $234.75M | $8.00M | $330.00M | $448.00M | $158.00M | $481.00M | $236.00M | $91.00M | $347.00M | $4.13B | $38.00M | $505.00M | $0.00 | $253.00M | $61.00M | $170.00M | $539.00M | $107.00M |
| QoQ Change | — | +0.0% | +0.0% | -96.6% | >999% | +35.8% | -64.7% | +204.4% | -50.9% | -61.4% | +281.3% | >999% | -99.1% | >999% | -100.0% | — | -75.9% | +178.7% | +217.1% | -80.1% |
| YoY Change | — | — | — | — | +40.6% | +90.8% | -32.7% | >999% | -28.5% | -79.7% | +119.6% | +758.8% | -83.9% | +454.9% | -100.0% | -93.9% | +60.5% | -66.3% | — | -57.7% |
Range$0.00 – $4.13B
CAGR-15.2%
Avg YoY Growth+459.7%
Median YoY Growth-28.5%
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's acquired ipr&d expense?
- Gilead Sciences (GILD) reported acquired ipr&d expense of $107.00M in Q1 2026.
- How has Gilead Sciences's acquired ipr&d expense changed year-over-year?
- Gilead Sciences's acquired ipr&d expense decreased by 57.7% year-over-year, from $253.00M to $107.00M.
- What is the long-term trend for Gilead Sciences's acquired ipr&d expense?
- Over 4 years (2021 to 2025), Gilead Sciences's acquired ipr&d expense has grown at a 2.2% compound annual growth rate (CAGR), from $939.00M to $1.02B.